业绩持续承压，迈克生物拟出售亏损子公司

Core Viewpoint - The company, Maike Biological, has decided to transfer its 51% stake in its subsidiary Shandong Maike Biological Technology Co., Ltd. for a transaction price of 17.41 million yuan, aiming to focus on core business and optimize resource allocation [1][3]. Financial Performance - In 2023, Shandong Maike reported revenues of approximately 243 million yuan and a net loss of about 11.04 million yuan. For 2024, revenues are projected to be around 227 million yuan with a net loss of approximately 1.91 million yuan [3]. - Maike Biological's revenue has declined over the years, with figures of 39.81 billion yuan in 2021, 36.08 billion yuan in 2022, 28.96 billion yuan in 2023, and 25.49 billion yuan in 2024. Corresponding net profits were 9.57 billion yuan, 7.08 billion yuan, 3.13 billion yuan, and 1.27 billion yuan respectively [4]. Strategic Decisions - The company aims to enhance market competitiveness and operational quality by divesting from loss-making assets, which is expected to alleviate operational pressure and facilitate capital recovery [3][4]. - Following the transfer, Maike Biological will establish an office in Shandong to manage and expand its dealer network in the region, ensuring that the core business operations remain unaffected [3]. Project Updates - The Maike Biological Tianfu International Biological City IVD Industrial Park project has experienced delays, with the expected operational status now pushed from June to December due to the need for extensive testing and certification of specialized equipment [5].